+Summary of Vaccine Protection against<unk>  Disease or infection Severe: protection retainedSymptomatic: possibly reduced protection Severe disease : AstraZeneca-Vaxzevria(1), Moderna(1), Pfizer-BioNTech(2) Symptomatic disease to : Pfizer-BioNTech(3) : Covaxin(1) : AstraZeneca-Vaxzevria(2) Infection : AstraZeneca-Vaxzevria(1), Pfizer-BioNTech(1) Effects on Neutralization (fully vaccinated) to : Anhui-ZIFIVAX(2), Covaxin(3) : Janssen(3), Moderna(3), Covishield(2) to : AstraZeneca-Vaxzevria(4), Pfizer-BioNTech(8) :Moderna & Pfizer-BioNTech(1)* to : Coronavac(2) : Neutralization reduces : Neutralization reduces 2 to : Neutralization reduces 5 to : Neutralization reduces &GreaterEqual; 10-fold * Moderna & Pfizer-BioNTech were evaluated together. WHO has not issued preventative measures against<unk>  specifically; non-pharmaceutical measures recommended to prevent wild type COVID-19 should still be effective. These would include washing hands, wearing a mask, maintaining distance from others, avoiding touching the mouth, nose or eyes, avoiding crowded indoor spaces with poor ventilation especially where people are talking, going to get tested if one develops symptoms and isolating if one becomes sick. Public Health authorities should continue to find infected individuals using testing, trace their contacts, and isolate those who have tested positive or been exposed. Event organizers should assess the potential risks of any mass gathering and develop a plan to mitigate these risks. See also Non-pharmaceutical intervention (epidemiology). ICMR found that convalescent sera of the COVID-19 cases and recipients of Bharat Biotech's BBV152 (Covaxin) were able to neutralise VUI B.1.617 although with a lower efficacy. Anurag Agrawal, the director of the Institute of Genomics and Integrative Biology (IGIB), said the study on the effectiveness of the available vaccines on lineage B.1.617 suggests that post-vaccination, the infections are milder. Anthony Fauci, the Chief Medical Advisor to the President of the United States, has also expressed his confidence regarding the preliminary results. In an interview on 28 April, he said: Another study by the Centre for Cellular and Molecular Biology (CCMB) in Hyderabad found Covishield (Oxford–AstraZeneca) vaccinated sera offers protection against lineage B.1.617. A study conducted by the Public Health England, has found that compared to those who were unvaccinated those who were vaccinated with either the Pfizer-BioNTech or AstraZeneca-Oxford had 33% less instances of symptomatic disease caused by the variant after the first dose. Among those who were two weeks after the receiving their second dose of the Pfizer-BioNTech vaccine 88% less subjects had symptomatic disease from the<unk>  variant versus those that were unvaccinated. Among those who were two weeks after the receiving their second dose of the AstraZeneca-Oxford vaccine 60% less subjects had symptomatic disease from the<unk>  variant versus those that were unvaccinated. A study by a group of researchers from the Francis Crick Institute, published in The Lancet, shows that humans fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralizing antibodies against the<unk>  variant compared to the original COVID-19 strain. In June 2021, Public Health England announced it had conducted a study which found that after two shots, the Pfizer-BioNTech vaccine and the AstraZeneca vaccine are respectively 96% and 92% effective at preventing hospitalisation from the<unk>  variant. On July 3, researchers from the universities of Toronto and Ottawa in Ontario, Canada, released a preprint study suggesting that the Moderna vaccine may be effective against death or hospitalization from the<unk>  variant. In a study of the University of Sri Jayewardenepura in July 2021 found the Sinopharm BIBP vaccine vaccine caused seroconversion in 95% of individuals studied that had received both doses of the vaccine. The rate was higher in 20-39 age group (98.9%) but slightly lower in the over 60 age group (93.3%). Neutralising antibodies were present among 81.25% of the vaccinated individuals studied. On 29 June 2021, the director of the Gamaleya Institute, Denis Logunov, said that Sputnik V is about 90% effective against the<unk>  variant. On July 21, researchers from Public Health England published a study finding that the Pfizer vaccine was 93.7% effective against symptomatic disease from<unk>  after 2 doses, while the Astrazeneca vaccine was 67% effective. On August 2, several experts expressed concern that achieving herd immunity may not currently be possible because the<unk>  variant is transmitted among those immunized with current vaccines. On August 10, a study showed that the full vaccination coverage rate is correlated inversely to the<unk>  mutation frequency in 16 countries (R-squared=0.878). Data strongly indicates that full vaccination against COVID-19 may slow down virus evolution.
SARS-CoV-2 Delta variant
SARS-CoV-2 Omicron variant
SARS-CoV-2 Epsilon variant
SARS-CoV-2 Mu variant
SARS-CoV-2 Gamma variant
SARS-CoV-2 Eta variant
SARS-CoV-2 Lambda variant
SARS-CoV-2 Alpha variant